

Elpro International Ltd

17th Floor, Nirmal, Nariman Point
Mumbai 400 021, India

T +91 22 2202 3075, +91 22 4029 9000
F +91 22 2202 7995

CIN: L51505MH1962PLC012425

August 29, 2025

To,
BSE Limited
Phiroze Jeejeebhoy
Towers Dalal Street
Mumbai - 400 001

Dear Sir / Ma'am,

Subject: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Pursuant to Regulation 30 of the SEBI Listing Regulations, we wish to inform you that the Elpro International Limited ("the Company") has acquired equity shares of "Supriya Lifescience Limited".

The disclosure pursuant to Regulation 30 of the SEBI Listing Regulations read with Para A of Part A of Schedule III of the SEBI Listing Regulations, is attached as "**Annexure A**".

This is for your information and record.

Thanking you,

For **Elpro International Limited**

Deepak
Kumar
Ajmera

Digitally signed by
Deepak Kumar
Ajmera
Date: 2025.08.29
18:44:22 +05'30'

Deepak Kumar Ajmera
Chief Financial Officer

Encl. as above

Elpro International Ltd

17th Floor, Nirmal, Nariman Point
Mumbai 400 021, India

T +91 22 2202 3075, +91 22 4029 9000
F +91 22 2202 7995

CIN: L51505MH1962PLC012425

Annexure A

| Sr. No. | Particulars | Details | | | | | | | | |
|-------------------------|--|--|-------------|--------------------|-------------------------|--------|--------------|------|--------------|---------------|
| 1. | Name of the target entity, details in brief such as size, turnover etc.: | Name of the target entity: Supriya Lifescience Limited Standalone Turnover as per last audited financials (FY 2024-25): <table><tr><th>Particulars</th><th>Amount (in Crores)</th></tr><tr><td>Revenue from Operations</td><td>696.50</td></tr><tr><td>Other income</td><td>9.81</td></tr><tr><td>Total</td><td>706.31</td></tr></table> | Particulars | Amount (in Crores) | Revenue from Operations | 696.50 | Other income | 9.81 | Total | 706.31 |
| Particulars | Amount (in Crores) | | | | | | | | | |
| Revenue from Operations | 696.50 | | | | | | | | | |
| Other income | 9.81 | | | | | | | | | |
| Total | 706.31 | | | | | | | | | |
| 2. | Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arms-length”: | No | | | | | | | | |
| 3. | Industry to which the entity being acquired belongs: | Pharmaceuticals | | | | | | | | |
| 4. | Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity): | Investment Purpose | | | | | | | | |
| 5. | Brief details of any governmental or regulatory approvals required for the acquisition: | N.A. | | | | | | | | |
| 6. | Indicative time period for completion of the acquisition: | N.A. | | | | | | | | |
| 7. | Nature of consideration - whether cash consideration or share swap and details of the same: | Cash consideration | | | | | | | | |
| 8. | Cost of acquisition or the price at which the shares are acquired: | INR 3.95 Crores | | | | | | | | |

Elpro International Ltd

17th Floor, Nirmal, Nariman Point
Mumbai 400 021, India

T +91 22 2202 3075, +91 22 4029 9000
F +91 22 2202 7995

CIN: L51505MH1962PLC012425

| 9. | Percentage of shareholding / control acquired and/or number of shares acquired: | Fresh Acquisition: 60,807 Equity Shares (Previous Holding: 1,193 Equity Shares) (Total Holding with Fresh Acquisition: 62,000 Equity Shares) | | | | | | | | | | | | | | | | | | | |
|-------------------------|---|--|---------------|--------------------|--|--|------------|------------|------------|-------------------------|--------|--------|--------|--------------|------|-------|-----|--------------|---------------|---------------|---------------|
| 10. | Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief): | Brief Background: Supriya Lifescience Ltd. is a cGMP compliant API Manufacturing Organization with leadership position across key and niche products. Supriya Lifescience Limited headquartered in Mumbai, India is a public listed generic pharmaceutical company established in 1987 dedicated to developing, commercializing APIs & FDFs to treat patients with various diseases and infections. Line of Business: Pharmaceuticals Website of the entity: https://www.supriyalifescience.com Date of Incorporation: 26/03/2008 Standalone Turnover of last 3 Financial Years: <table><tr><th rowspan="2">Particulars</th><th colspan="3">Amount (in Crores)</th></tr><tr><th>FY 2024-25</th><th>FY 2023-24</th><th>FY 2022-23</th></tr><tr><td>Revenue from Operations</td><td>696.50</td><td>570.34</td><td>460.93</td></tr><tr><td>Other income</td><td>9.81</td><td>10.63</td><td>9.5</td></tr><tr><td>Total</td><td>706.31</td><td>580.97</td><td>470.43</td></tr></table> Country in which the target has presence: India | Particulars | Amount (in Crores) | | | FY 2024-25 | FY 2023-24 | FY 2022-23 | Revenue from Operations | 696.50 | 570.34 | 460.93 | Other income | 9.81 | 10.63 | 9.5 | Total | 706.31 | 580.97 | 470.43 |
| Particulars | Amount (in Crores) | | | | | | | | | | | | | | | | | | | | |
| | FY 2024-25 | FY 2023-24 | FY 2022-23 | | | | | | | | | | | | | | | | | | |
| Revenue from Operations | 696.50 | 570.34 | 460.93 | | | | | | | | | | | | | | | | | | |
| Other income | 9.81 | 10.63 | 9.5 | | | | | | | | | | | | | | | | | | |
| Total | 706.31 | 580.97 | 470.43 | | | | | | | | | | | | | | | | | | |